The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.

CONCLUSIONS: Consequently, targeted therapies based on the interaction of PI3K inhibition with BRCA1 mutations or HR deficiency in TNBC may be a promising strategy for the treatment of patients with TNBC.
PMID: 31804921 [PubMed - in process]

Source: J Pharm Pharm Sci - December 6, 2019 Category: Drugs & Pharmacology Authors: Guney Eskiler G Tags: J Pharm Pharm Sci Source Type: research